I did some calcs this afternoon to calculate approximate EBT/share for 2017/2018 financial year. Pretty cheap for a growing business if you ask me.
I have made some assumptions with the 31% growth of Indue and its effect on revenue. The information has been gathered from Dec Half yearly, latest quarterly update with revenue forecast and the Indue acquisition upgrade announcements. I have not factored in organic growth into the estimate.
My broker (finds cash flow positive small caps for me that a support internally in his firm) is adamant that its all down to the CR. I think the full year report will be the ignition for this stock.
Column 1
Column 2
0
Share Price
$0.0250
1
EBT/share
$0.0056
2
EBT Multiple
4.50
Column 1
Column 2
Column 3
Column 4
Column 5
0
Cash Flow Type
Original company
Figure
Calc basis
Factor used in calc
1
Revenue
Star
$12,000,000
As per forcast Mar 2017 3mil/qtr
2
Indue
$5,370,000
Increase in customer base
31%
3
NeoICP
$80,000
4
Cost of Sales
Star
-$6,653,800
Gross COS as factor of revenue from haly yearly + 15% cost saving from Indue intergration
65%/-15%
5
Indue
-$3,490,000
Gross COS as factor of revenue (includes wages/depreciation+amortorization)
